OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
March 24, 2023
Moderna and Generation Bio have announced a strategic collaboration to develop non-viral genetic medicines.
Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.
March 21, 2023
BioNTech will receive an exclusive worldwide license from OncoC4 to develop and commercialize its anti-CTLA-4 mAb candidate for solid tumor indications.
March 17, 2023
Polyplus’ LipidBrick is designed to expand the scope of lipid nanoparticle formulation usage in mRNA therapeutics and vaccine development.
Stevanato Group will support development and production of pre-fillable syringes for use in Recipharm’s soft mist inhalers.
Predictive Oncology and Cancer Research Horizons have partnered to pursue development of cancer drugs utilizing the PEDAL platform.
Sandoz, a Novartis division, is expected to invest at least $400 million to build a new biologics manufacturing facility in Lendava, Slovenia, to support growing demand for biosimilars.
Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.
The collaboration between Genuv and Celltrion will utilize Genuv's proprietary mouse platform for antibody discovery.
March 15, 2023
A phase-appropriate analytical development strategy is crucial, especially for complex (formulated) drug substances.
